Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

655 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Statin therapy in Alzheimer's disease.
Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P. Sparks DL, et al. Among authors: connor d. Acta Neurol Scand Suppl. 2006;185:78-86. doi: 10.1111/j.1600-0404.2006.00689.x. Acta Neurol Scand Suppl. 2006. PMID: 16866915 Review.
A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT).
Sparks DL, Lopez J, Connor D, Sabbagh M, Seward J, Browne P; Alzheimer's Disease Cholesterol-Lowering Treatment Team. Sparks DL, et al. Among authors: connor d. J Mol Neurosci. 2003;20(3):407-10. doi: 10.1385/JMN:20:3:407. J Mol Neurosci. 2003. PMID: 14501025 Clinical Trial.
Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Sparks DL, et al. Among authors: connor dj. Acta Neurol Scand Suppl. 2006;185:3-7. doi: 10.1111/j.1600-0404.2006.00690.x. Acta Neurol Scand Suppl. 2006. PMID: 16866904 Clinical Trial.
Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C. Sparks DL, et al. Among authors: connor dj. Curr Alzheimer Res. 2005 Jul;2(3):343-53. doi: 10.2174/1567205054367900. Curr Alzheimer Res. 2005. PMID: 15974900 Clinical Trial.
655 results